Generation of non-genetically modified, CAR-like, NK cells

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Natural killer (NK) cell therapy shows promise for cancer treatment but lacks target specificity, limiting clinical benefit.
• Chimeric antigen receptor (CAR)-NK cells offer improved specificity but involve complex manufacturing.
• A novel approach is needed for targeted NK cell therapy without genetic modification.

Purpose of the Study:

• To develop a targeted NK cell therapy platform using antibody-dependent cell-mediated cytotoxicity (ADCC) without genetic modification.
• To engineer modified monoclonal antibodies (Pin-mAbs) with enhanced affinity for CD16a on NK cells.
• To evaluate the efficacy of antibody-armed NK cells in targeting cancer cells.

Main Methods:

• Ex vivo expanded NK (eNK) cells were generated from umbilical cord blood.
• Monoclonal antibodies were engineered with Pin mutations to increase CD16a affinity.
• eNK cells were armed with anti-CD20 or anti-CD19 Pin-mAbs and tested in vitro and in vivo.

Main Results:

• The CD16a/Pin-mAb interaction was stable, conferring long-term specificity to armed eNK cells.
• Pin-mAb armed eNK cells induced ADCC specifically against antigen-expressing target cells.
• Simultaneous arming with multiple Pin-mAbs enhanced efficacy against heterogeneous cancer populations in vivo.

Conclusions:

• The Pin technology offers an off-the-shelf NK cell therapy platform.
• It generates CAR-like NK cells without genetic modification, enabling targeted tumor antigen elimination.
• This platform facilitates targeting of multiple tumor antigens for enhanced therapeutic outcomes.